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Introduction 
Langerhans cell histiocytosis (LCH) is a group of rare, 
clonal proliferative disorders with a broad spectrum 
of clinical manifestations, ranging from benign 
cutaneous lesions to malignant multisystem disease. 
Langerhans cell histiocytosis is the most common 
histiocytic disorder in the pediatric population, with 
an incidence of three to five cases per million [1]. It is 
believed to be underdiagnosed owing to the self-
healing nature of certain variants and lack of proper 
clinical identification. 
Congenital self-limited LCH was first described by 
Hashimoto and Pritzker in 1973 [2]. It typically 
manifests at birth or in the post-natal period and 
cutaneous findings vary, but it most often presents 
as a widespread eruption of red-to-brown 
papulonodules [3]. To date, only 40 single lesion 
cases have been documented in the literature. We 
present a case of single lesion LCH in a full-term male 
infant with interesting morphology. 
 
Case Synopsis 
A full-term male infant presented with an 
asymptomatic lesion of the posterior left thigh that 
was noted within the first 24 hours of life. Physical 
examination revealed a painless, 6 millimeter, well-
demarcated, papule encircled by erythema with 
central hemorrhage (Figure 1). The papule was 
heterogeneous in color with black to grey in the 
center and yellow to green along the periphery. The 
newborn was well appearing and there was no family 
history of dermatologic or autoimmune conditions. 
The differential diagnosis was broad and included 
ecthyma, candidiasis, herpes simplex virus, 
congenital varicella, lymphoma, aplasia cutis, LCH, 
mastocytosis, and juvenile xanthogranuloma. 
Prenatal screening was negative for group B 
streptococcus. Swabs for bacterial cultures and 
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monitor for multisystem recurrence. 
Volume 25 Number 8| August 2019| 
25(8):9 
 
 
- 2 - 
Dermatology Online Journal  ||  Photo Vignette
fungal cultures, and viral polymerase chain reactions 
for HSV were negative. A punch biopsy specimen 
was obtained and sent for histopathological analysis. 
The histopathological evaluation of the skin biopsy 
specimen revealed epidermal ulceration (Figure 2A) 
in association with a subjacent dense dermal 
infiltrate of histiocytoid appearing cells manifesting 
indistinct cell borders and lightly eosinophilic 
cytoplasm (Figure 2B). These cells exhibited 
irregular, eccentrically disposed nuclei with focal 
'bean-shaped' contours and a finely dispersed 
chromatin (Figures 2C, D); mitoses were rare. 
Although the epidermis was mostly denuded, in a 
small area of intact epidermis the dermal infiltrate 
was focally epidermotropic. In addition, there was a 
polymorphous inflammatory background 
comprising small mature lymphocytes and 
numerous eosinophils. Utilizing immunohisto-
chemistry, lesional cells stained strongly positive for 
CD1a (Figure 3A) and Langerin (Figure 3B). These 
findings were consistent with a diagnosis of LCH. 
The patient was referred to the oncology 
department for a more extensive workup, including 
hematologic and coagulation studies, liver function 
tests, musculoskeletal exam, chest X-ray, and BRAF 
 
Figure 1. Well demarcated papule encircled by erythema with 
central hemorrhage on the patient’s posterior thigh. 
 
Figure 2. A) The biopsy shows an area of epidermal denudement 
in association with a subjacent nodular infiltrate extending into 
the deeper reticular dermis. H&E, 10×. B) Higher power 
magnification shows a striking dense histiocytoid infiltrate 
accompanied by numerous lymphocytes and eosinophils. H&E, 
20×. C) Higher power magnification demonstrates the classic 
cytology that is encountered in LCH. In particular there are 
nodular aggregates of histiocytoid appearing cells that are 
remarkable for their oval to bean shaped nuclei showing a, finely 
dispersed chromatin and eccentric disposition within the cell. 
They have a morphology clearly disparate to the background 
inflammatory cell populace which is predominated by 
lymphocytes and as well there are scattered eosinophils. H&E, 
100×. D) H&E, 400×. 
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genetic testing. The workup was negative for any 
signs of systemic disease and the papule healed 
without intervention in three weeks. No new lesions 
have developed. 
 
Case Discussion 
Congenital self-limited LCH is a rare, benign variant 
of LCH. In typical unilesional cases, it presents as a 
painless papule or nodule with ulceration or an 
overlying scale crust [3]. In our case, the lesion was 
infectious-appearing as there was an oozing, 
pustular component. Patients presenting with a 
solitary lesion are uniquely challenging for the 
differential diagnosis is broad. However, 
distinguishing between self-limited disease and 
systemic LCH is crucial as systemic LCH can become 
aggressive and require chemotherapy [4]. 
The overall prognosis for single lesion skin limited 
LCH is excellent and most lesions spontaneously 
resolve within 4-18 weeks [3]. However, skin findings 
cannot predict systemic disease and obtaining an 
oncology consultation is recommended for further 
evaluation [5]. Patients should undergo general 
evaluation, which includes a thorough physical 
examination, blood count and differential, 
coagulation studies, and liver function testing [5]. 
Radiographic skeletal survey and chest X-ray are 
additionally indicated to assess for bone and 
pulmonary involvement [5]. Testing for BRAF 
mutations is newly included in of the work-up of LCH 
since the literature suggests that oncogenic BRAF 
V600E mutations may play a role in its pathogenesis 
with implications for targeted treatment [6]. More 
recently, it has been suggested that circulating cell-
free DNA with detectable BRAF V600E mutations 
may be a useful biomarker for predicting high risk 
disease and monitoring response to therapy [7]. 
Multisystem LCH involving the bone marrow, spleen, 
or liver portends a poor prognosis and as many as 8-
13% congenital LCH cases may later result in 
multisystem relapse [4, 5]. Although our patient’s 
work up was negative for underlying systemic 
disease, he continues to be followed for recurrence 
or dissemination. It is important for clinicians to 
know that regression of cutaneous disease cannot 
rule out future dissemination and close long-term 
follow-up with a multidisciplinary team is necessary. 
 
Conclusion 
Dermatologists should consider LCH in the 
differential diagnosis for lesions of varying 
morphology in children. Given the inconsistent and 
unpredictable nature of LCH and large variety in 
clinical presentation, heightened vigilance is 
required even when limited disease is suspected. 
This case highlights the need for long-term follow-up 
to monitor for disease recurrence or dissemination, 
which carries a poor prognosis.  
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Figure 3. The lesional cells were positive for A) CD1a and B) 
Langerin by immunohistochemistry, 100×. 
A 
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